Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors-Reference-Cited by-同舟云学术

Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors

Published:2010-07-04 Issue:1 Volume:11 Page:
ISSN:1471-2350
Container-title:BMC Medical Genetics
language:en
Short-container-title:BMC Med Genet

Author:

Merkelbach-Bruse Sabine,Dietmaier Wolfgang,Füzesi Laszlo,Gaumann Andreas,Haller Florian,Kitz Julia,Krohn Antje,Mechtersheimer Gunhild,Penzel Roland,Schildhaus Hans-Ulrich,Schneider-Stock Regine,Simon Ronald,Wardelmann Eva

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Genetics

Link

http://link.springer.com/content/pdf/10.1186/1471-2350-11-106.pdf

Reference30 articles.

1. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom A, Blay J, Leyvraz S, Stul M, Casali P, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006, 42: 1093-1103. 10.1016/j.ejca.2006.01.030.

2. Heinrich M, Owzar K, Corless C, Hollis D, Borden E, Fletcher C, Ryan C, von Mehren M, Blanke C, Rankin C, et al: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008, 26: 5360-5367. 10.1200/JCO.2008.17.4284.

3. Wardelmann E, Büttner R, Merkelbach-Bruse S, Schildhaus H: Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch. 2007, 451: 743-749. 10.1007/s00428-007-0473-9.

4. Lasota J, Miettinen M: Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008, 53: 245-266. 10.1111/j.1365-2559.2008.02977.x.

5. Miettinen M, Lasota J: Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol. 2006, 23: 70-83. 10.1053/j.semdp.2006.09.001.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Justification of direct Sanger sequencing application for detection of KIT and PDGFRα gene mutations in formalin-fixed, paraffin-embedded samples from gastrointestinal stromal tumours;Journal of Clinical Pathology;2019-10-24

2. STR technique for the detection of contamination by exogenous DNA in paraffin blocks and histological slides;Surgical and Experimental Pathology;2019-09-09

3. KIT exon 11 and PDGFRA exon 18 gene mutations in gastric GIST: proposal of a short panel for predicting therapeutic response;Surgical and Experimental Pathology;2018-11-21

4. Gastrointestinal Stromal Tumor: Genotype Frequency and Prognostic Relevance;Applied Immunohistochemistry & Molecular Morphology;2018-03

5. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events;Human Pathology;2017-04